Next Article in Journal
TGF-β and BMPR2 Signaling in PAH: Two Black Sheep in One Family
Next Article in Special Issue
Resveratrol Attenuates Staphylococcus Aureus-Induced Monocyte Adhesion through Downregulating PDGFR/AP-1 Activation in Human Lung Epithelial Cells
Previous Article in Journal
Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors
Open AccessReview

Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol?

by You-Lin Tain 1,2 and Chien-Ning Hsu 3,*
1
Departments of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
2
Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
3
Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(9), 2584; https://doi.org/10.3390/ijms19092584
Received: 20 July 2018 / Revised: 28 August 2018 / Accepted: 29 August 2018 / Published: 31 August 2018
(This article belongs to the Special Issue Health Benefits of Resveratrol)
Metabolic syndrome (MetS) is a mounting epidemic worldwide. MetS can start in early life, in a microenvironment that is now known as the developmental origins of health and disease (DOHaD). The concept of DOHaD also offers opportunities for reprogramming strategies that aim to reverse programming processes in early life. Resveratrol, a polyphenolic compound has a wide spectrum of beneficial effects on human health. In this review, we first summarize the epidemiological and experimental evidence supporting the developmental programming of MetS. This review also presents an overview of the evidence linking different molecular targets of resveratrol to developmental programming of MetS-related disorders. This will be followed by studies documenting resveratrol as a reprogramming agent to protect against MetS-related disorders. Further clinical studies are required in order to bridge the gap between animal models and clinical trials in order to establish the effective dose and therapeutic duration for resveratrol as a reprogramming therapy on MetS disorders from developmental origins. View Full-Text
Keywords: developmental origins of health and disease (DOHaD); hypertension; metabolic syndrome; nitric oxide; nutrient-sensing signal; obesity; oxidative stress; renin-angiotensin system; resveratrol developmental origins of health and disease (DOHaD); hypertension; metabolic syndrome; nitric oxide; nutrient-sensing signal; obesity; oxidative stress; renin-angiotensin system; resveratrol
Show Figures

Figure 1

MDPI and ACS Style

Tain, Y.-L.; Hsu, C.-N. Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol? Int. J. Mol. Sci. 2018, 19, 2584.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop